Partnership
Dr. GPCR x Celtarys Reseach
Empowering medicinal biochemists
Celtarys empowers medicinal biochemists by providing innovative fluorescent probes that de-risk the pre-clinical drug discovery phase. Our proprietary conjugation technology and unparalleled scientific expertise ensure researchers can confidently advance their projects with greater precision and reliability.
About Celtarys Research
Celtarys Research develops and commercializes new chemical tools to spread the use of fluorescence-based methods in the pre-clinical phase of drug discovery. Our proprietary chemical conjugation technology allows us to develop in a competitive manner and short time (<3 months) customized fluorescent ligands with optimal pharmacological and photophysical properties for any druggable target.
We have a catalogue of over 30 fluorescent ligands for different families of GPCRs, including adenosine, dopamine, serotonin, cannabinoid and muscarinic receptors. We also offer our expertise in the form of custom development services, where we tackle challenging targets and synthesize probes with the most suitable properties for your needs.
Meet the Celtarys Team
Wilson Gomes
CEO
Wilson Gomes holds a Mechanical Engineering degree, an MBA from the University of North Carolina, and completed the General Management Program at Harvard Business School. He has over 20 years of experience in the medtech and diagnostics industries, having held senior roles at Johnson & Johnson and Danaher across the EMEA region in sales, marketing, and general management.
He joined Celtarys as CEO in 2024, where he is responsible for driving strategy and growth. His focus is on expanding commercial reach and accelerating the adoption of the company’s GPCR assay technologies.
Maria Majellaro
Co-Funder and CSO
Dr. Maria Majellaro earned her degree in Pharmaceutical Chemistry and Technology from the University of Bari and completed her PhD in Biomolecular Sciences in Pharmacology and Medicine as “Doctor Europeus” in 2018. She then joined the University of Santiago de Compostela as a postdoctoral researcher in Prof. Eddy Sotelo’s group, contributing to the IGNICIA tech transfer project and the validation of Celtarys’ core technology.
In 2021, she co-founded Celtarys and now leads the company’s scientific direction. Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools for pharma, biotech, and academic partners.
Podcast Episode
Baking Molecules, Building Probes: When Chemists Think Like Biologists
Episode #168 • Dr. GPCR Talks with Dr. Maria Majellaro
"We always start with the problem, then generate the right compound using our chemistry. It’s about enabling biology.”
Our Partnership
We’re proud to partner with Celtarys Research, a leading innovator in fluorescent ligand technology, to bring high-performance chemical tools to the global GPCR community.
Celtarys develops fluorescently labeled ligands designed for real-time, non-radioactive GPCR assays—enabling researchers to visualize binding events, track kinetics, and explore receptor biology with clarity and speed. Their proprietary chemistry platform produces conjugates with exceptional affinity and pharmacological profiles, helping teams design better experiments and uncover new therapeutic opportunities.
Through this partnership, Celtarys is featured across the Dr. GPCR ecosystem—from our weekly newsletter and podcast to University courses and the searchable Partner Directory—ensuring their tools reach scientists where they are.
“These ligands don’t just light up receptors—they open new dimensions in receptor research,” says Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR. “We’re excited to connect the GPCR community with tools that advance discovery.”
“Dr. GPCR gives us a unique platform to reach scientists solving today’s toughest GPCR challenges,” adds Wilson Gomes, CEO of Celtarys Research. “Together, we’re accelerating the path from receptor biology to real-world impact.”
Services & Expertise
Fluorescent Probes
Innovative fluorescent probes that de-risk the pre-clinical drug discovery phase with optimal pharmacological properties.
Custom Development
Customized fluorescent ligands developed in less than 3 months with optimal properties for any druggable target.
GPCR Expertise
Specialized knowledge in adenosine, dopamine, serotonin, cannabinoid and muscarinic receptors for advanced research.
Product Catalog
Address
Avda. Mestre Mateo 2, Santiago de Compostela, 15706, Spain
Website